



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/TG/2025-26/104

October 11, 2025

To The Manager, BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol - Biocon

Subject: Company Statement

Dear Sir/Madam,

This is to inform that subsequent to the inauguration of the Company's first manufacturing site in the United States, located in Cranbury, New Jersey, in September, that will support capacity expansion and supply chain efficiency in the region, the facility underwent a GMP inspection by the U.S. FDA.

The inspection concluded with 1 observation which the Company will address within the stipulated time and is not expected to have any impact on business operations.

The Cranbury facility represents a strategic advancement of the Company's operations in the United States, enabling faster access to Biocon's vertically integrated portfolio of products, benefitting patients in the region. With some products having already been commissioned from this site and additional launches in the pipeline, the facility will play a key role in furthering Biocon's mission to expand access to high-quality, affordable therapies worldwide.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Rajesh U. Shanoy
Company Secretary and Compliance Officer
M. No.: ACS 16328